Cargando…

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice

Despite the availability of anti-retroviral therapy, HIV-1 infection remains a massive burden on healthcare systems. Bacillus Calmette-Guérin (BCG), the only licensed vaccine against tuberculosis, confers protection against meningitis and miliary tuberculosis in infants. Recombinant BCG has been use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kilpeläinen, Athina, Saubi, Narcís, Guitart, Núria, Olvera, Alex, Hanke, Tomáš, Brander, Christian, Joseph, Joan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789536/ https://www.ncbi.nlm.nih.gov/pubmed/31382453 http://dx.doi.org/10.3390/vaccines7030078

Ejemplares similares

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
por: Saubi, Narcís, et al.
Publicado: (2020)

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
por: Kilpeläinen, Athina, et al.
Publicado: (2019)

Vaccination with an HIV T-Cell Immunogen (HTI) Using DNA Primes Followed by a ChAdOx1-MVA Boost Is Immunogenic in Gut Microbiota-Depleted Mice despite Low IL-22 Serum Levels
por: Elizalde-Torrent, Aleix, et al.
Publicado: (2023)

HTI
por: Main, Max
Publicado: (2004)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
por: Folegatti, Pedro M., et al.
Publicado: (2019)

A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination
por: Natung, Tanie, et al.
Publicado: (2023)

MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
por: Broset, Esther, et al.
Publicado: (2019)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice
por: Chen, Chun-Wei, et al.
Publicado: (2022)

Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients
por: Vaishya, Raju, et al.
Publicado: (2021)

Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
por: Kang, Yu Min, et al.
Publicado: (2021)

Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
por: Mahant, Aakash, et al.
Publicado: (2017)

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens
por: Antrobus, Richard D, et al.
Publicado: (2014)

COVID‐19 vaccine (ChAdOx1 nCoV‐19 Corona virus vaccine (Recombinant) – COVISHIELD related MS relapse
por: Mathew, Thomas, et al.
Publicado: (2021)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

The COVID‐19 vaccine ChAdOx1‐S is not contaminated with sulfated glycosaminoglycans
por: Alban, Susanne, et al.
Publicado: (2022)

Prolonged febrile illness following first dose of ChAdOx1
por: Caruana Dingli, Michael, et al.
Publicado: (2023)

Pre-Clinical Development of BCG.HIVA(CAT), an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2012)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Chronic spontaneous urticaria following ChAdOx1-S COVID-19 vaccination
por: Suan, Dan, et al.
Publicado: (2022)

Myelin Oligodendrocyte Glycoprotein-Associated Disorders Post-ChAdOx1 Vaccination
por: Maramattom, Boby Varkey
Publicado: (2022)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Delayed large local reaction to the adenovirus-vectored (ChAdOx1) vaccine
por: Grobusch, Martin P., et al.
Publicado: (2021)

Central nervous system adverse events after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2022)

De novo psoriasis induced by ChAdOx1-S COVID 19 vaccine()
por: Zaiem, Ahmed, et al.
Publicado: (2022)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
por: de Laat, Bas, et al.
Publicado: (2022)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey
por: Kaur, Sukhpal, et al.
Publicado: (2022)

A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19
por: Chen, Chih-Jung, et al.
Publicado: (2022)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
por: Alharbi, Naif Khalaf, et al.
Publicado: (2017)

CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant
por: Fumagalli, Marcilio Jorge, et al.
Publicado: (2022)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Adequacy of Hemodialysis Serves as an Independent Predictor of Humoral Response to ChAdOx1 Prime-Boost Vaccination in Hemodialysis Patients
por: Chen, Chun-Yu, et al.
Publicado: (2022)

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
por: Holm, Sverre, et al.
Publicado: (2021)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uvq0a48ll18trj4j1i0ma83g3q